Craig Asher is a co-leader of OMX Ventures, an early-stage biotech venture capital firm dedicated to advancing innovations at the intersection of data and biology. Alongside his partners, Craig has helped build a portfolio of 27 early-stage companies across therapeutics, bio tools, synthetic biology, and diagnostics, guiding them toward transformative milestones and favorable exits.
Before forming OMX Ventures in 2020, Craig had a successful track record as an early-stage biotech investor. From 2009 to 2020, he partnered with management teams at QuantaLife, 10X Genomics, Twist Bioscience, Ginkgo Bioworks, and CD Diagnostics, helping these companies grow into industry leaders. These investments, centered on generating and applying high-quality biological data, returned 4x net to Craig and his investor syndicate. Craig’s early experiences as a manufacturing engineer, followed by roles at Trigo Technologies (later IBM), helped shape his expertise in data systems and predictive algorithms—foundations that continue to inform his approach to biotech investment.
Craig graduated from Stanford University and earned an MBA and MS in Industrial Engineering from Northwestern University. Outside of OMX, he enjoys studying biology and chemistry, traveling (fluent in French, German, and Spanish), running, visiting art museums, cheering for Fulham FC and the Washington Nationals, and exploring the intersection of science, business, and economics.
